Impact of a combination of a calcium antagonist and a β-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 5, 1997, Pages 979-988

  Lesnik, Philippe ^a   Dachet, Christiane ^a   Petit, Laure ^a   Moreau, Martine ^a   Griglio, Sabine ^a   Brudi, Philippe ^b   John Chapman, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Zeneca Pharma   (France)

Author keywords

atenolol; LDL; macrophages; monocytes; nifedipine; oxidation

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NIFEDIPINE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MEMBRANE TRANSPORT; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LIPID OXIDATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030948956     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.5.979     Document Type: Article

References (12)

1. Blankenhorn DH. Blood lipids and human coronary artery atherosclerosis regression: the angiographic evidence. Curr Opin Lipidol. 1991;2:234-239.
2. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Cleland FGF, Krikler DM. Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J. 1993;69(suppl):S54-S62.
4. Schmitz G, Hankowitz J, Kovacs EM. Cellular processes in atherogenesis: potential target of calcium channel blockers. Atherosclerosis. 1991;88:109-132.
5. Cruickshank JM, Smith JC. The beta-receptor, atheroma and cardiovascular damage. Pharmacol Ther. 1989;42:385-404.
6. Shimamoto T, Sunaga T. The concentration and blebbing of endothelial cells accompanied by acute infiltration of plasma substances into the vessel wall and their prevention. Excerpta Med Int Congr Ser. 1972;269:3-31.
7. Leren P. Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. Am J Med. 1987;82:31-35.
8. Orekhov AN, Ruda MY, Baldenkov BN, Tertov VV, Khashimov KA, Ryong LH, Lyakishev AA, Koslov SG, Tkachuk VA, Smirnov VN. Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol. 1988;61:1116-1117.
9. Orekhov AN, Andrianova I, Rekhter MD, Tertov VV, Andreeva ER, Ragimov SE, Mironov AA. Beta blockers: propanolol, metaprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Atherosclerosis. 1992;95:77-85.
10. Jenkins RR, Del-Signore CM, Sauer P, Skelly C. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Lipids. 1992;27:539-542.
11. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RR, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 1993;22:922-928.
12. Schmitz G, Robeneck H, Beuck M, Krause R, Schurek A, Niemann R. Calcium antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis. 1988;8:46-56.